Immunotech Biopharm (HKSE:06978) EPS (Basic): HK$-0.46 (TTM As of Dec. 2025)


HKSE:06978 Immunotech Biopharm Ltd HKSE:06978
20 GF Score
Price HK$0.54
! 3 Warning Signs
View Full Analysis

What is Immunotech Biopharm EPS (Basic)?

Immunotech Biopharm HKSE:06978 -1.82% 20 EPS (Basic) is HK$-0.46 as of Dec. 2025. GuruFocus rates HKSE:06978 with a GF Score™ of 20/100. The stock has 3 warning signs investors should review.

Immunotech Biopharm's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was HK$-0.21. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.46.

Immunotech Biopharm's EPS (Diluted) for the six months ended in Dec. 2025 was HK$-0.21. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.46.

Immunotech Biopharm's EPS without NRI for the six months ended in Dec. 2025 was HK$-0.21. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.46.

During the past 3 years, the average EPS without NRI Growth Rate was 7.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 18.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, Immunotech Biopharm's highest 3-Year average EPS without NRI Growth Rate was 28.70% per year. The lowest was -115.20% per year. And the median was 7.50% per year.

Immunotech Biopharm  (HKSE:06978) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Immunotech Biopharm EPS (Basic) Related Terms

Immunotech Biopharm EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Immunotech Biopharm's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunotech Biopharm EPS (Basic) Chart

Immunotech Biopharm Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial -0.78 -0.64 -0.65 -0.37 -0.46

Immunotech Biopharm Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.42 -0.18 -0.20 -0.25 -0.21
HKSE:06978
20GF Score
Immunotech Biopharm Ltd HKSE:06978
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunotech Biopharm EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Immunotech Biopharm's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-254.954-0)/549.003
=-0.46

Immunotech Biopharm's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-112.331-0)/538.324
=-0.21

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of HK$-0.46 mean?
Immunotech Biopharm (HKSE:06978) has a EPS (Basic) of HK$-0.46 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Immunotech Biopharm and its competitors.
Is Immunotech Biopharm's EPS (Basic) too high?
Immunotech Biopharm's current EPS (Basic) is HK$-0.46. Overall, Immunotech Biopharm has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Immunotech Biopharm's EPS (Basic) compare to VRTX and REGN?
Immunotech Biopharm's EPS (Basic) of HK$-0.46 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Immunotech Biopharm and its competitors. Immunotech Biopharm's current EPS (Basic) is HK$-0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunotech Biopharm stock overvalued right now?
Immunotech Biopharm (HKSE:06978) has a current EPS (Basic) of HK$-0.46. The current EPS (Basic) is HK$-0.46. Immunotech Biopharm's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Immunotech Biopharm (HKSE:06978), the current EPS (Basic) is HK$-0.46 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immunotech Biopharm Business Description

Address No.1 Kangding Street, 8th Floor, Block 1, Guosheng Technology Park, Beijing Economic-technological Development Area, Beijing, CHN, 100176
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
20GF Score

Get the complete analysis for HKSE:06978

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.54
Price